Subject Index

A

Acetylcholine 147
p-acetylenic GABA 51
Activation 111
Active avoidance 260, 410
Acute psychoses 16
Adenosine 136, 421
Adenylate cyclase 464
Adipsia 328
Adrenal glands 39
Adrenalectomy 39
Age 186
Aggression 39, 86
Aggressive behavior 313
Aging 286
Albumin 204
Alcohol 303, 379
Alcoholics 64
Alprazolam 194
Alzheimer's disease 147, 247
Aminopropanesulfonic acid 51
4-Aminopyridine 266
Amphetamine 25, 186, 328, 400
d-Amphetamine 111, 207
Analgesia 34, 39
Animal models 379
Anorexia 25
Antagonism 344
Antagonism tests 449
Anticholinergic 69
Anticholinesterase 69
Anticonvulsant drugs 449
Antidepressants 7, 253, 283
Antidepressive treatment 212
Antiepileptic drugs 337
Anxiety 278, 322
Anxiety disorders 130
Apomorphine 12, 161, 238, 351
Arecoline 266
Arginine vasopressin 430
Arousal 371, 490
Arousal drug effects 194
Aversion 43, 225
Avoidance 266
Avoidance conditioning 410

B

Baboon 167
Baclofen 51, 480
Behavioral suppression 473
Behavioral tolerance 414
Behavioural despair 81
Behavioural development 434
Benzodiazepine 322
Benzodiazepine binding 322
Benzodiazepines 130, 186, 233, 473
Beta-adrenergic blocker 219
Bicuculline 51
Body weight 198
Body weight loss 141
Brain 152
Brain syndrome 292
Bromocriptine 12
Butyrophenones 161

C

Caffeine 272, 344, 421
Carbamazepine 59
β-carbolines 64
Catalepsy 12
Cathinone 328
Caudate 400
Central drug administration 351
Cerebral ventricles 292
Cerebrospinal fluid 59
CGS 8216 225
Chlordiazepoxide 219
Chlorimipramine 7
p-Chloroamphetamine 260
Chlorpromazine 7
Cholinergic 266
Cholinergic sensitivity 247
Cholinergic system 247, 357
Cigarette 334
Cigarette smoking 198
Citalopram 253
Classical conditioning 90
Clinical state 364
Clonidine 425, 490
Cluster analysis 337
CNS 127
Cocaine 178, 396
Codeine 468
Cognition 344
Cognitive behavior 303
Cognitive conflict 303
Cognitive processing 178
Combined drug effects 421
Compensatory conditioning 101
Conditioned avoidance 124
Conditioned reinforcement 454
Conditioned taste aversion 238, 328, 454
Conditioning 94
Conflict behavior 242
Convulsants 379
Cross-tolerance 34
Cytidine 136

D

D-1 and D-2 receptors 308
Day-night rhythm 286
Decision making 303
Defeat 39
Defense 86
Delay of reward 473
Delayed matching 357
Dementia 147
Dependence 141, 334
Depot neuroleptic 364
Depressants 379
Depression 157, 173, 253
Desipramine 116
Dextroamphetamine sulfate 298
Diazepam 167, 186, 194, 225, 242, 322, 344, 473
Differential punishment of high rates of response (DPH) 219
Differential reinforcement of low rates of response (DRL) 77, 219
5,6-Dihydroxytryptamine 260
5,7-Dihydroxytryptamine 400
Dipipanone 468
DN-1417 141
Dopamine 12, 119, 308, 313, 351, 454, 461, 480
Dopamine receptor antagonist 454
Dopamine receptors 161, 368
Double-blind trial 30
Droperidol 161
Drug discrimination 1, 233, 368
Drug effects 371
Drug interaction 344
Drug preference 186
Drugs as discriminative stimuli 449
Duration of drug action 161
Duration of punishment 473
Dynorphin$_{1-13}$ 216

E

Eating rate 351
Eating time 351
EEG 178, 337, 430
Elderly patients 212
β-Endorphin 216
Environment distinctiveness 101
Ethanol 43, 90, 94, 152, 414, 461
Ethanol-induced impairment 20
Event related potentials 178

F

Fear 278
Feeding 286
Feeding behaviour 351
Fenfluramine 25
Fimbria-fornix 357
Fixed-interval schedule 272
Fixed-ratio schedule 272
Fluphenazine 30
Fluphenazine decanoate 55
Fluphenazine hydrochloride 55
Fluprazine hydrochloride 86
Food consumption 198
Food intake 25
Forced swim test 119
Forskolin 464
Furosemide 20

G

GABA 157, 379
$GABA_A$ receptor 51
$GABA_B$ receptor 51
Generalization tests 449
GLC 55
α_1-glycoprotein 204
Go-no go discrimination learning 434

H

Habenula 81
Habituation 101, 400
Haloperidol 12, 161, 351
Harman 64
Heart rate 34
Herrnstein's equation 207

Subject Index

A

Acetylcholine 147
p-acetylenic GABA 51
Activation 111
Active avoidance 260, 410
Acute psychoses 16
Adenosine 136, 421
Adenylate cyclase 464
Adipsia 328
Adrenal glands 39
Adrenalectomy 39
Age 186
Aggression 39, 86
Aggressive behavior 313
Aging 286
Albumin 204
Alcohol 303, 379
Alcoholics 64
Alprazolam 194
Alzheimer's disease 147, 247
Aminopropanesulfonic acid 51
4-Aminopyridine 266
Amphetamine 25, 186, 328, 400
d-Amphetamine 111, 207
Analgesia 34, 39
Animal models 379
Anorexia 25
Antagonism 344
Antagonism tests 449
Anticholinergic 69
Anticholinesterase 69
Anticonvulsant drugs 449
Antidepressants 7, 253, 283
Antidepressive treatment 212
Antiepileptic drugs 337
Anxiety 278, 322
Anxiety disorders 130
Apomorphine 12, 161, 238, 351
Arecoline 266
Arginine vasopressin 430
Arousal 371, 490
Arousal drug effects 194
Aversion 43, 225
Avoidance 266
Avoidance conditioning 410

B

Baboon 167
Baclofen 51, 480
Behavioral suppression 473
Behavioral tolerance 414
Behavioural despair 81
Behavioural development 434
Benzodiazepine 322
Benzodiazepine binding 322
Benzodiazepines 130, 186, 233, 473
Beta-adrenergic blocker 219
Bicuculline 51
Body weight 198
Body weight loss 141
Brain 152
Brain syndrome 292
Bromocriptine 12
Butyrophenones 161

C

Caffeine 272, 344, 421
Carbamazepine 59
β-carbolines 64
Catalepsy 12
Cathinone 328
Caudate 400
Central drug administration 351
Cerebral ventricles 292
Cerebrospinal fluid 59
CGS 8216 225
Chlordiazepoxide 219
Chlorimipramine 7
p-Chloroamphetamine 260
Chlorpromazine 7
Cholinergic 266
Cholinergic sensitivity 247
Cholinergic system 247, 357
Cigarette 334
Cigarette smoking 198
Citalopram 253
Classical conditioning 90
Clinical state 364
Clonidine 425, 490
Cluster analysis 337
CNS 127
Cocaine 178, 396
Codeine 468
Cognition 344
Cognitive behavior 303
Cognitive conflict 303
Cognitive processing 178
Combined drug effects 421
Compensatory conditioning 101
Conditioned avoidance 124
Conditioned reinforcement 454
Conditioned taste aversion 238, 328, 454
Conditioning 94
Conflict behavior 242
Convulsants 379
Cross-tolerance 34
Cytidine 136

D

D-1 and D-2 receptors 308
Day-night rhythm 286
Decision making 303
Defeat 39
Defense 86
Delay of reward 473
Delayed matching 357
Dementia 147
Dependence 141, 334
Depot neuroleptic 364
Depressants 379
Depression 157, 173, 253
Desipramine 116
Dextroamphetamine sulfate 298
Diazepam 167, 186, 194, 225, 242, 322, 344, 473
Differential punishment of high rates of response (DPH) 219
Differential reinforcement of low rates of response (DRL) 77, 219
5,6-Dihydroxytryptamine 260
5,7-Dihydroxytryptamine 400
Dipipanone 468
DN-1417 141
Dopamine 12, 119, 308, 313, 351, 454, 461, 480
Dopamine receptor antagonist 454
Dopamine receptors 161, 368
Double-blind trial 30
Droperidol 161
Drug discrimination 1, 233, 368
Drug effects 371
Drug interaction 344
Drug preference 186
Drugs as discriminative stimuli 449
Duration of drug action 161
Duration of punishment 473
Dynorphin$_{1-13}$ 216

E

Eating rate 351
Eating time 351
EEG 178, 337, 430
Elderly patients 212
β-Endorphin 216
Environment distinctiveness 101
Ethanol 43, 90, 94, 152, 414, 461
Ethanol-induced impairment 20
Event related potentials 178

F

Fear 278
Feeding 286
Feeding behaviour 351
Fenfluramine 25
Fimbria-fornix 357
Fixed-interval schedule 272
Fixed-ratio schedule 272
Fluphenazine 30
Fluphenazine decanoate 55
Fluphenazine hydrochloride 55
Fluprazine hydrochloride 86
Food consumption 198
Food intake 25
Forced swim test 119
Forskolin 464
Furosemide 20

G

GABA 157, 379
$GABA_A$ receptor 51
$GABA_B$ receptor 51
Generalization tests 449
GLC 55
α_1-glycoprotein 204
Go-no go discrimination learning 434

H

Habenula 81
Habituation 101, 400
Haloperidol 12, 161, 351
Harman 64
Heart rate 34
Herrnstein's equation 207

5-HIAA 253
High salt-low salt diet 20
Hippocampus 400
Hoeboard 400
Homing performance 434
Human information processing 178
Humans 90
HVA 253
6-Hydroxydopamine 77
5-Hydroxytryptamine 173, 308
Hypertension 238
Hypnotic action 406
Hypnotics 107
Hypothalamus 461
Hypothermia 141

I

Imipramine 7, 157, 204, 278
Immobility 283
Inbred mice 124
Individual variation 55
Initial peak 55
Initial treatment phenomenon 242
Intraventricular injection 292

K

Kappa opioid 286
Khat 328

L

Learning 69, 344, 490
Lithium 111
Liver histology 64
Locomotor activity 51, 434
Locomotor patterns 400
Long-acting esters 30
Long-sleep and Short-sleep mice 379
Long-term memory 390
Lorazepam 130
Low plasma levels 55

M

Male rat 127
Manic-depressive illness 59
Melatonin 116
Memory 147, 216, 266, 344
Mental rehearsal 90
Meprobamate 225
Methamphetamine 357
3-Methoxy-4-hydroxyphenyl-glycol 59
Methylclonazepam 130
Methylnaloxonium 410
Mianserin 204
Mice 141, 322, 410, 421, 434
Microinjection 39
Microstructural analysis 351
Midazolam 233
Middle aged 390
Mineralocorticoid 20
Monoamine oxidase 152
Monoaminergic agonists 119
Mood 344
MOPEG 253
Morphine 1, 34, 39, 425
Morphine abstinence syndrome 141
Morphine analgesic tolerance 101
Motivation 334
Motor activity 313
Motor activity-6-hydroxydopamine-catecholamines 484
MSLT 194
Muscarinic receptors 127

N

N^6-(phenylisopropyl)-adenosine 272
Naloxone 39, 141, 225, 286, 461, 468
Naltrexone 1
Naltrexone methobromide 1
/-Nantradol 425
Neuroleptics 30, 161
Nicotine 198, 266, 334
Nicotinic acid 390
Nociception 260
Nomifensine 81
Noradrenaline 77, 119
Noradrenaline uptake 116
Noradrenergic 464
Norepinephrine 59, 157
Nucleus accumbens 119
Nucleus basalis 357
Nutrient selection 25

O

Offense 86
Offensive attack 86
Old aged 390
Ontogeny of amphetamine and scopolamine reactivity 434
Open field locomotor activity 119
Operant behavior 283, 414
Operant behaviour 207
Opiate 286
Opiate antagonist 1, 410
Opioid peptides 216
Opioids 468
Oral and injectable 55
Orthostatic blood pressure 212
Overshadowing 101
Oxaprotiline 116
Oxazepam 434
Oxotremorine 266

P

P200 178
P300 178
Pain 39
Panic disorder 278
Passive avoidance 322
Pentobarbitone 233
Pentylenetetrazol 337
Peptide hormone 141
Perception of sleep 107
Performance testing 194
Perphenazine 16
Perseveration 400
Phenylpiperazines 86
Physostigmine 147, 266, 357
PIA 421
Picrotoxin 225
Pigeons 7, 449
Pimozide 454
Place conditioning 43, 225
Placebo analgesia 468
Plasma amino acids 253
Plasma concentration 16
Plasma fluphenazine 55
Plasma proteins 204
Platelet 152
Prenatal benzodiazepine treatment 434
Primate behavior 69
Problem solving 303
Prolactin 30, 461
Propranolol 219
Prostaglandin synthetase inhibitor 20
Protein binding 204
Psychomotor 344
Psychomotor performance 371
Psychosis 111, 292
Punishment 7, 322
Pupilography 116

Q

Quarternary naloxone 410

R

Rat 43, 77, 81, 101, 119, 207, 219, 225, 238, 260, 292, 308, 328, 337, 351, 357, 368, 425, 430, 473
Rats 233, 414
Reaction time 167
Receptor sensitivity 464
Receptors 12
Reflexive fighting 86
Regional cerebral blood flow 298
Reinforcement 43
Reinforcing properties 186
Renin-angiotensin system 20
Repeated acquisition 69
Reserpine 157
Residual tolerance 414
Response rate 283
Reward 225
Rheumatoid arthritis 204
Rhythm 286
Ro22-2586 308
RU24213 308

S

SCH 23390 308
Schedule-controlled behavior 7, 421
Schedule-controlled responding 272
Schizophrenia 111, 292, 364
Scopolamine 247, 357
Selected lines 379
Self-administration 328
Sensory register 390
Sensory threshold 167
Serotonin 119, 313, 400
Serotonin reuptake inhibition 253
Serum levels 364
Sexual behavior 127
Shock avoidance 425
Shock-elicited aggression 86
Short-term memory 357, 390
Shuttle-box avoidance 434
Side effects 30
Situational variables 43
SKF 38393 368
SKF 82526 368
Sleep 136, 406
Sleep EEG 406
Social behavior 303
Social isolation 313

Sodium valproate 225
Spectral analysis 430
Spinal serotonin 260
Spironolactone 20
Startle 278, 396
Stereotypy 161, 308
Stimulants 178
Stress 81
Strychnine 396
Subjective estimates 107
Sucrose 25
Swimming 283
Swimming behaviour 81
Sympathetic nervous system 77
Systolic time intervals 212

T

Tardive dyskinesia 480
Δ^9-THC 34
Therapeutic window 16
Thioridazine 351
THIP 51
Time of day 186
Tolerance 34, 90, 94, 194, 242, 313, 322, 414, 425
Tourniquet test 468
Toxicity 328
Trace amines 64
TRH-MK-771 141
Triazolam 167
Tricyclic antidepressants 278
Tryptophan 173, 313

U

U-50,488H 286
Uridine 136

V

Valerian 406
Valproic acid 449
Variable-interval schedules 207
Vasopressin 124, 238
Vasopressin analogs 238
Vasopressin antagonist 238

W

Water reinforcement 283
Withdrawal 334

X

Xanthinol nicotinate 390
^{133}Xenon inhalation technique 298

Y

Y-maze escape 410
Young aged 390

Z

Zuclopenthixol decanoate 364

Contents

Aaes-Jørgensen, T., see Jørgensen, A., et al. 364

Agmo, A., Giordano, M.
The locomotor-reducing effects of GABAergic drugs do not depend on the $GABA_A$ receptor 51

Ahlenius, S., Larsson, K.
Central muscarinic receptors and male rat sexual behavior: Facilitation by oxotremorine but not arecoline or pilocarpine in methscopolamine pretreated animals, 127

Alleva, E., Laviola, G., Tirelli, E., Bignami, G.
Short-, medium-, and long-term effects of prenatal oxazepam on neurobehavioural development of mice 434

Alpern, H.P., see McIntyre, T.D. 379

Altamura, A.C., Curry, S.H., Montgomery, S., Wiles, D.H.
Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients 30

Annear, W.C., Vogel-Sprott, M.
Mental rehearsal and classical conditioning contribute to ethanol tolerance in humans 90

Ansseau, M., Doumont, A., Thiry, D., von Frenckell, R., Collard, J.
Initial study of methylclonazepam in generalized anxiety disorder 130

Arendt, J., see Checkley, S.A., et al. 116

Baastrup, P.C., see Jørgensen, A., et al. 364

Bach, L., see Dafters, R. 101

Balderer, G., Borbély, A.A.
Effect of valerian on human sleep 406

Baldessarini, R.J., see Campbell, A., et al. 161

Ballenger, J.C., see Post, R.M., et al. 59

Barnes, E., see Haroutunian, V., et al. 266

Beller, S.A., Overall, J.E., Swann, A.C.
Efficacy of oral physostigmine in primary degenerative dementia 147

Belmaker, R.H., see Hamburger, R., et al. 124

Beninger, R.J., see Hoffman, D.C. 454

Berge, O.-G., see Ögren, S.O., et al. 260

Bhargava, H.N., Matwyshyn, G.A.
Comparative effects of thyrotropin releasing hormone, MK-771 and DN-1417 on morphine abstinence syndrome 141

Bignami, G., see Alleva, E., et al. 434

Bird, D.C., Holloway, F.A., Carney, J.M.
Schedule-controlled behavior as an index of the development and loss of ethanol tolerance in the rat 414

Biziere, K., see Santucci, V., et al. 337

Bjerkenstedt, L., Edman, G., Flyckt, L., Hagenfeldt, L., Sedvall, G., Wiesel, F.A.
Clinical and biochemical effects of citalopram, a selective 5-HT reuptake inhibitor – a dose-response study in depressed patients 253

Blanchard, D.C., see Flannelly, K.J., et al. 86

Blanchard, R.J., see Flannelly, K.J., et al. 86

Bliwise, N.G., see Seidel, W.F., et al. 371

Bluthé, R.-M., Dantzer, R., Mormède, P., Le Moal, M.
Specificity of aversive stimulus properties of vasopressin 238

Borbély, A.A., see Balderer, G. 406

Bowen, D.J., see Grunberg, N.E., et al. 198

Bowers, M.B., see Glazer, W.M., et al. 480

Bradshaw, C.M., see Morley, M.J., et al. 207

Brady, J.V., see Lukas, S.E., et al. 167

Browne, R.G., see Suzdak, P.D. 464

Bunney, B.S., see Glazer, W.M., et al. 480

Bunney Jr, W.E., see van Kammen, D.P., et al. 111

Burke, C.A., see Posner, J. 468

Burton, S., see Checkley, S.A., et al. 116

Campbell, A., Baldessarini, R.J., Teicher, M.H., Kula, N.S.
Prolonged antidopaminergic actions of single doses of butyrophenones in the rat 161

Carney, J.M., see Bird, D.C., et al. 414

Casper, R.C., see Chang, S.S., et al. 55

Cassella, J.V., Davis, M.
Fear-enhanced acoustic startle is not attenuated by acute or chronic imipramine treatment in rats 278

Chang, S.S., Javaid, J.I., Dysken, M.W., Casper, R.C., Janicak, P.G., Davis, J.M.
Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia 55

Checkley, S.A., Thompson, C., Burton, S., Franey, C., Arendt, J.
Clinical studies of the effect of (+) and (−)-oxaprotiline upon noradrenaline uptake 116

Christensen, P., Thomson, H.Y., Pedersen, O.L., Thayssen, P., Oxhøj, H., Kragh-Sørensen, P., Gram, L.F.
Cardiovascular effects of amitriptyline in the treatment of elderly depressed patients 212

Clincke, G.H.C., see Sahgal, A. 374

Cohen, R.M., see Sunderland, T., et al. 247

Cohen, S.A., see Seidel, W.F., et al. 194, 371

Collard, J., see Ansseau, M., et al. 130

Crane, R.A., see Radulovacki, M., et al. 136

Crow, T.J., see Joseph, M.H., et al. 442

Crow, T.J., see Frith, C.D., et al. 490

Crowley, T.J., Macdonald, M.J., Zerbe, G.
Naltrexone: No effect on simian social and motor behavior 250

Curry, S.H., see Altamura, A.C., et al. 30

Dafters, R., Bach, L.
Absence of environment-specificity in morphine tolerance acquired in non-distinctive environments habituation or stimulus overshadowing?, 101

Damm, H., see Rommelspacher, H., et al. 64

Dantzer, R., see Bluthé, R.-M., et al. 238

Danysz, W., see Plaźnik, A., et al. 119

Davis, J.M., see Chang, S.S., et al. 55

Davis, K.L., see Haroutunian, V., et al. 266

Davis, M., see Cassella, J.V. 278

Davis, M., see Harty, T.P. 396

De Almeida, M.A.M.R., see Izquierdo, I., et al. 216

de Graaf, J.S., see Martinez Jr, J.L. 410

De Leon-Jones, F., see Tabakoff, B., et al. 152

De Swart, J.H., see Loriaux, S.M., et al. 390

de Wit, H., Uhlenhuth, E.H., Johanson, C.E.
Drug preference in normal volunteers: Effects of age and time of day 186

Deakin, J.F.W., see Joseph, M.H., et al. 442

Deijen, J.B., see Loriaux, S.M., et al. 390

Dement, W.C., see Seidel, W.F., et al. 194, 371

Dencker, S.J., see Jørgensen, A., et al. 364

Dews, P.B., see Glowa, J.R., et al. 421

Docherty, J.P., see van Kammen, D.P., et al. 111

Doumont, A., see Ansseau, M., et al. 130

Dowdy, J., see Frith, C.D., et al. 490

Dunne, M.P.
An interpretation of some conflicting evidence regarding the effects of scopolamine upon vigilance 126

Dunnett, S.B.
Comparative effects of cholinergic drugs and lesions of nucleus basalis or fimbria-fornix on delayed matching in rats 357

Duvilanski, B., see Seilicovich, A., et al. 461

Dysken, M.W., see Chang, S.S., et al. 55

Edman, G., see Bjerkenstedt, L., et al. 253

Ehlers, C.L., Reed, T.K., Wang, M., Lebrun, C.J., Koob, G.F.
EEG effects of subcutaneous and intracerebroventricular injections of arginine vasopressin in the rat 430

Elias, J., see Grupp, L.A., et al. 20

Emiliano, V.R., see Izquierdo, I., et al. 216

Ervin, F.R., see Young, S.N., et al. 173

Evans, J.A.C., see Thornton, E.W., et al. 81

Ferrier, I.N., see Frith, C.D., et al. 490

Flannelly, K.J., Muraoka, M.Y., Blanchard, D.C., Blanchard, R.J.
Specific anti-aggressive effects of fluprazine hydrochloride 86

Flyckt, L., see Bjerkenstedt, L., et al. 253

Fournier, M., see Santucci, V., et al. 337

Franey, C., see Checkley, S.A., et al. 116

Frith, C.D., Dowdy, J., Ferrier, I.N., Crow, T.J.
Selective impairment of paired associate learning after administration of a centrally-acting adrenergic agonist (clonidine) 490

Garcha, H.S., Rose, I.C., Stolerman, I.P.
Midazolam cue in rats: Generalization tests with anxiolytic and other drugs 233

Gately, P.F., Poon, S.L., Segal, D.S., Geyer, M.A.
Depletion of brain serotonin by 5,7-dihydroxytryptamine alters the response to amphetamine and the habituation of locomotor activity in rats 400

Geyer, M.A., see Gately, P.F., et al. 400

Ghoneim, M.M., see Loke, W.H., et al. 344

Gianutsos, G., see Suzdak, P.D. 157

Giordano, M., see Agmo, A. 51

Glazer, W.M., Moore, D.C., Bowers, M.B., Bunney, B.S., Roffman, M.
The treatment of tardive dyskinesia with baclofen 480

Glowa, J.R., Sobel, E., Malaspina, S., Dews, P.B.
Behavioral effects of caffeine, (−)N-((R)-1-methyl-2-phenylethyl)-adenosine (PIA), and their combination in the mouse 421

Goldberg, S.R., Prada, J.A., Katz, J.L.
Stereoselective behavioral effects of N^6-phenylisopropyladenosine and antagonism by caffeine 272

Goudie, A.J., Newton, T.
The puzzle of drug-induced conditioned taste aversion: Comparative studies with cathinone and amphetamine 328

Gram, L.F., see Kristensen, C.B., et al. 204

Gram, L.F., see Christensen, P., et al. 212

Gram, L.F., see Jørgensen, A., et al. 364

Gravem, A., see Jørgensen, A., et al. 364

Gray, J.A., see Salmon, P., et al. 77

Gray, J.A., see Salmon, P. 219

Grunberg, N.E., Bowen, D.J., Maycock, V.A., Nespor, S.M.
The importance of sweet taste and caloric content in the effects of nicotine on specific food consumption 198

Grupp, L.A., Elias, J., Perlanski, E., Stewart, R.B.
Modification of ethanol-induced motor impairment by diet, diuretic, mineralocorticoid, or prostaglandin synthetase inhibitor 20

Grupp, L.A., see Stewart, R.B. 43

Hagenfeldt, L., see Bjerkenstedt, L., et al. 253

Hamburger, R., Sela, A., Belmaker, R.H.
Differences in learning and extinction in response to vasopressin in six inbred mouse strains 124

Hancock, S., see Picker, M., et al. 449

Hansen, L.B., Larsen, N.-E.
Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice 16

Haroutunian, V., Barnes, E., Davis, K.L.
Cholinergic modulation of memory in rats 266

Harris, C., see Thornton, E.W., et al. 81

Harty, T.P., Davis, M.
Cocaine: Effects on acoustic startle and startle elicited electrically from the cochlear nucleus 396

Herning, R.I., Jones, R.T., Hooker, W.D., Tulunay, F.C.
Information processing components of the auditory event related potential are reduced by cocaine 178

Hienz, R.D., see Lukas, S.E., et al. 167

Hine, B.
Morphine and Δ^9-tetrahydrocannabinol: Two-way cross tolerance for antinociceptive and heart-rate responses in the rat 34

Hinrichs, J.V., see Loke, W.H., et al. 344

Hirst, M., see Kavaliers, M., et al. 286

Hoffman, D.C., Beninger, R.J.
The effects of pimozide on the establishment of conditioned reinforcement as a function of the amount of conditioning 454

Hoffman, P.L., see Tabakoff, B., et al. 152

Holloway, F.A., see Bird, D.C. et al. 414

Holtzmann, S.G., see Locke, K.W. 1

Hooker, W.D., see Herning, R.I., et al. 178

Izquierdo, I., De Almeida, M.A.M.R., Emiliano, V.R.
Unlike-β-endorphin, dynorphin$_{1-13}$ does not cause retrograde amnesia for shuttle avoidance or inhibitory avoidance learning in rats 216

Janicak, P.G., see Chang, S.S., et al. 55

Javaid, J.I., see Chang, S.S., et al. 55

Jimerson, D.C., see Post, R.M., et al. 59

Johanson, C.E., see de Wit, H., et al. 186

Johansson, C., see Ögren, S.O., et al. 260

Johnstone, E.C., see Joseph, M.H., et al. 442

Jones, R.T., see Herning, R.I., et al. 178

Joseph, M.H., Risby, D., Crow, T.J., Deakin, J.F.W., Johnstone, E.C., Lawler, P.
MHPG excretion in endogenous depression: Relationship to clinical state and the effects of ECT 442

Jørgensen, A., Aaes-Jørgensen, T., Gravem, A., Dencker, S.J., Baastrup, P.C., Gram, L.F.
Zuclopenthixol decanoate in schizophrenia: Serum levels and clinical state 364

Kamien, J.B., Woolverton, W.L.
The D_1 dopamine agonist SKF 38393 functions as a discriminative stimulus in rats 368

Katz, J.L., see Goldberg, S.R., et al. 272

Kavaliers, M., Teskey, G.C., Hirst, M.
The effects of aging on daynight rhythms of Kappa opiate-mediated feeding in the mouse 286

Kazandjian, A., see Spyraki, C., et al. 225

Keane, P., see Santucci, V., et al. 337

Klemm, W.R.
Experimental catalepsy is both enhanced and disrupted by apomorphine 12

Kline Jr, J., Reid, K.H.
The acute periventricular injury syndrome: A possible animal model for psychotic disease 292

Koob, G.F., see Ehlers, C.L., et al. 430

Kostowski, W., see Plaźnik, A., et al. 119

Kragh-Sørensen, P., see Kristensen, C.B., et al. 204

Kragh-Sørensen, P., see Christensen, P., et al. 212

Kristensen, C.B., Gram, L.F., Kragh-Sørensen, P.
Mianserin protein binding in serum and plasma from healthy subjects and patients with depression and rheumatoid arthritis 204

Kula, N.S., see Campbell, A., et al. 161

Kuusinen, J., Nystedt, L.
The influence of alcohol on cognitive conflict 303

Lake, C.R., see Post, R.M., et al. 59

Lamb, R.J., McMillan, D.E.
Some effects of chlorimipramine and imipramine on the schedule-controlled behavior of the pigeon 7

Larsen, N.-E., see Hansen, L.B. 16

Larsson, K., see Ahlenius, S. 127

Lasley, S.M., Thurmond, J.B.
Interaction of dietary tryptophan and social isolation on territorial aggression, motor activity, and neurochemistry in mice 313

Laviola, G., see Alleva, E., et al. 434

Lawler, P., see Joseph, M.H., et al. 442

Le Moal, M., see Bluthé, R.-M., et al. 238

Lebrun, C.J., see Ehlers, C.L., et al. 430

Lee, J.M., see Tabakoff, B., et al. 152

Linnoila, M., see Post, R.M., et al. 59

Locke, K.W., Holtzmann, S.G.
Characterization of the discriminative stimulus effects of centrally administered morphine in the rat 1

Loke, W.H., Hinrichs, J.V., Ghoneim, M.M.
Caffeine and diazepam: Separate and combined effects on mood, memory, and psychomotor performance 344

Loriaux, S.M., Deijen, J.B., Orlebeke, J.F., De Swart, J.H.
The effects of nicotinic acid and xanthinol nicotinate on human memory in different categories of age. A double blind study 390

Lukas, S.E., Hienz, R.D., Brady, J.V.
Effects of diazepam and triazolam on auditory and visual thresholds and reaction times in the baboon 167

Macdonald, M.J., see Crowley, T.J., et al. 250

Malaspina, S., see Glowa, J.R., et al. 421

Marder, S.R., see van Kammen, D.P., et al. 111

Martinez Jr, J.L., de Graaf, J.S.
Quaternary naloxone enhances acquisition of a discriminated Y-maze *escape* and a one-way active avoidance task in mice 410

Mathew, R.J., Wilson, H.
Dextroamphetamine-induced changes in regional cerebral blood flow 298

Matwyshyn, G.A., see Bhargava, H.N. 141

Maycock, V.A., see Grunberg, N.E., et al. 198

McIntyre, T.D., Alpern, H.P.
Reinterpretation of the literature indicates differential sensitivities of long-sleep and short-sle mice are not specific to alcohol 379

McMillan, D.E., see Lamb, R.J. 7

Melchior, C.L., Tabakoff, B.
Features of environment-dependent tolerance to ethanol 94

Michaud, J.-C., see Santucci, V., et al. 337

Miczek, K.A., Thompson, M.L., Shuster, L.
Naloxone injections into the periaqueductal grey area and arcuate nucleus block analgesia in defeated mice 39

Mokler, D.J., Rech, R.H.
Mechanisms of the initial treatment phenomenon to diazepam in the rat 242

Molloy, A.G., see Pugh, M.T., et al. 308

Montgomery, S., see Altamura, A.C., et al. 30

Moore, D.C., see Glazer, W.M., et al. 480

Morley, M.J., Bradshaw, C.M., Szabadi, E.
The effect of *d*-amphetamine on operant behaviour maintained under variable-interval schedules of reinforcement 207

Mormède, P., see Bluthé, R.-M., et al. 238

Morre, M., see Santucci, V., et al. 337

Mueller, E.A., see Sunderland, T., et al. 247

Muñoz Maines, V., see Seilicovich, A., et al. 461

Muraoka, M.Y., see Flannelly, K.J., et al. 86

Murphy, D.L., see Sunderland, T., et al. 247

Muscat, R., see Willner, P., et al. 351

Nespor, S.M., see Grunberg, N.E., et al. 198

Newton, T., see Goudie, A.J. 328

Nystedt, L., see Kuusinen, J. 303

O'Boyle, K.M., see Pugh, M.T., et al. 308

O'Donnell, J.M., Seiden, L.S.
Effect of the experimental antidepressant AHR-9377 on performance during differential reinforcement of low response rate 283

Ögren, S.O., Berge, O.-G., Johansson, C.
Involvement of spinal serotonergic pathways in nociception but not in avoidance learning 260

Olds, M.E., Yuwiler, A.
Comparison of hyperactivity in adult rats induced by neonatal intraventricular 6-hydroxydopamine following pargyline or desmethylimipramine treatment 484

Orlebeke, J.F., see Loriaux, S.M., et al. 390

Orthen-Gambill, N.
Sucrose intake unaffected by fenfluramine but suppressed by amphetamine administration 25

Overall, J.E., see Beller, S.A., et al. 147

Oxhøj, H., see Christensen, P., et al. 212

Pedersen, O.L., see Christensen, P., et al. 212

Penetar, D.M.
The effects of atropine, benactyzine, and physostigmine on a repeated acquisition baseline in monkeys 69

Perlanski, E., see Grupp, L.A., et al. 20

Picker, M., Wallace, S., Hancock, S., Poling, A.
Discriminative stimulus properties of valproic acid in the pigeon 449

Pihl, R.O., see Young, S.N., et al. 173

Plaźnik, A., Danysz, W., Kostowski, W.
A stimulatory effect of intra-accumbens injections of noradrenaline on the behavior of rats in the forced swim test 119

Poling, A., see Picker, M., et al. 449

Poon, S.L., see Gately, P.F., et al. 400

Posner, J., Burke, C.A.
The effects of naloxone on opiate and placebo analgesia in healthy volunteers 468

Post, R.M., Rubinow, D.R., Uhde, T.W., Ballenger, J.C., Lake, C.R., Linnoila, M., Jimerson, D.C., Reus, V.
Effects of carbamazepine on noradrenergic mechanisms in affectively ill patients 59

Prada, J.A., see Goldberg, S.R., et al. 272

Pugh, M.T., O'Boyle, K.M., Molloy, A.G., Waddington, J.L.
Effects of the putative D-1 antagonist SCH 23390 on stereotyped behaviour induced by the D-2 agonist RU24213 308

Radulovacki, M., Virus, R.M., Rapoza, D., Crane, R.A.
A comparison of the dose response effects of pyrimidine ribonucleosides and adenosine on sleep in rats 136

Rapoza, D., see Radulovacki, M., et al. 136

Rech, R.H., see Mokler, D.J. 242

Reed, T.K., see Ehlers, C.L., et al. 430

Reid, K.H., see Kline Jr, J. 292

Rettori, V., see Seilicovich, A., et al. 461

Reus, V., see Post, R.M., et al. 59

Risby, D., see Joseph, M.H., et al. 442

Roffman, M., see Glazer, W.M., et al. 480

Rommelspacher, H., Damm, H., Schmidt, L., Schmidt, G.
Increased excretion of harman by alcoholics depends on events of their life history and the state of the liver 64

Rose, I.C., see Garcha, H.S., et al. 233

Rosenblatt, J.E., see van Kammen, D.P., et al. 111

Rubinow, D.R., see Post, R.M., et al. 59

Rubio, M., see Seilicovich, A., et al. 461

Russell, M.A.H., see West, R.J. 334

Sahgal, A., Clincke, G.H.C.
A comparison of different methods of assessing patterns of responding in discrete trial choice procedures 374

Salmon, P., Gray, J.A.
Comparison between the effects of propranolol and chlordiazepoxide on timing behaviour in the rat 219

Salmon, P., Stanford, C., Gray, J.A.
The effect of peripheral noradrenaline depletion on responding on a schedule of differential reinforcement of low rates of response (DRL) 77

Santucci, V., Fournier, M., Keane, P., Simiand, J., Michaud, J.-C., Morre, M., Biziere, K.
EEG effects of IV infusion of pentylenetetrazol in rats
A model for screening and classifying antiepileptic compounds, 337

Schmidt, G., see Rommelspacher, H., et al. 64

Schmidt, L., see Rommelspacher, H., et al. 64

Schneider, H.H., see Stephens, D.N. 322

Schneider-Helmert, D.
Overestimations of hypnotic drug effects by insomniacs – a hypothesis 107

Sedvall, G., see Bjerkenstedt, L., et al. 253

Segal, D.S., see Gately, P.F., et al. 400

Seidel, W.F., Cohen, S.A., Bliwise, N.G., Dement, W.C.
Buspirone:
An anxiolytic without sedative effect, 371

Seidel, W.F., Cohen, S.A., Wilson, L., Dement, W.C.
Effects of alprazolam and diazepam on the daytime sleepiness of non-anxious subjects 194

Seiden, L.S., see O'Donnell, J.M. 283

Seilicovich, A., Rubio, M., Duvilanski, B., Muñoz Maines, V., Rettori, V.
Inhibition by naloxone of the rise in hypothalamic dopamine and serum prolactin induced by ethanol 461

Sela, A., see Hamburger, R., et al. 124

Shuster, L., see Miczek, K.A., et al. 39

Simiand, J., see Santucci, V., et al. 337

Simon, P., see Thiébot, M.-H., et al. 473

Smith, J.B.
Effects of single and repeated daily injections of morphine, clonidine, and *l*-nantradol on avoidance responding of rats 425

Smith, S., see Young, S.N., et al. 173

Sobel, E., see Glowa, J.R., et al. 421

Soubrié, P., see Thiébot, M.-H., et al. 473

Spyraki, C., Kazandjian, A., Varonos, D.
Diazepam-induced lace preference conditioning: Appetitive and antiaversive properties 225

Stanford, C., see Salmon, P., et al. 77

Stephens, D.N., Schneider, H.H.
Tolerance for the benzodiazepine diazepam in an animal model of anxiolytic activity 322

Stewart, R.B., Grupp, L.A.
Some determinants of the motivational properties of ethanol in the rat:
Concurrent administration of food or social stimuli 43

Stewart, R.B., see Grupp, L.A., et al. 20

Stolerman, I.P., see Garcha, H.S., et al. 233

Sunderland, T., Tariot, P., Murphy, D.L., Weingartner, H., Mueller, E.A., Cohen, R.M.
Scopolamine challenges in Alzheimer's disease 247

Suzdak, P.D., Browne, R.G.
The effect of chronic in vivo infusion of forskolin on noradrenergic receptor sensitivity 464

Suzdak, P.D., Gianutsos, G.
GABAergic effects of reserpine following chronic treatment 157

Swann, A.C., see Beller, S.A., et al. 147

Szabadi, E., see Morley, M.J., et al. 207

Tabakoff, B., Lee, J.M., De Leon-Jones, F., Hoffman, P.L.
Ethanol inhibits the activity of the B form of monoamine oxidase in human platelet and brain tissue 152

Tabakoff, B., see Melchior, C.L. 94

Tariot, P., see Sunderland, T., et al. 247

Teicher, M.H., see Campbell, A., et al. 161

Teskey, G.C., see Kavaliers, M., et al. 286

Thayssen, P., see Christensen, P., et al. 212

Thiébot, M.-H., Soubrié, P., Simon, P.
Is delay of reward mediated by shock-avoidance behavior a critical target for anti-punishment effects of diazepam in rats? 473

Thiry, D., see Ansseau, M., et al. 130

Thompson, C., see Checkley, S.A., et al. 116

Thompson, M.L., see Miczek, K.A., et al. 39

Thomson, H.Y., see Christensen, P., et al. 212

Thornton, E.W., Evans, J.A.C., Harris, C.
Attenuated response to nomifensine in rats during a swim test following lesion of the habenula complex 81

Thurmond, J.B., see Lasley, S.M. 313

Tirelli, E., see Alleva, E., et al. 434

Towell, A., see Willner, P., et al. 351

Tulunay, F.C., see Herning, R.I., et al. 178

Uhde, T.W., see Post, R.M., et al. 59

Uhlenhuth, E.H., see de Wit, H., et al. 186

van Kammen, D.P., Docherty, J.P., Marder, S.R., Rosenblatt, J.E., Bunney Jr, W.E.
Lithium attenuates the activation-euphoria but not the psychosis induced by *d*-amphetamine in schizophrenia 111

Varonos, D., see Spyraki, C., et al. 225

Virus, R.M., see Radulovacki, M., et al. 136

Vogel-Sprott, M., see Annear, W.C. 90

von Frenckell, R., see Ansseau, M., et al. 130

Waddington, J.L., see Pugh, M.T., et al. 308

Wallace, S., see Picker, M., et al. 449

Wang, M., see Ehlers, C.L., et al. 430

Weingartner, H., see Sunderland, T., et al. 247

West, R.J., Russell, M.A.H.
Pre-abstinence smoke intake and smoking motivation as predictors of severity of cigarette with-drawal symptoms 334

Wiesel, F.A., see Bjerkenstedt, L., et al. 253

Wiles, D.H., see Altamura, A.C., et al. 30

Willner, P., Towell, A., Muscat, R.
Apomorphine anorexia: A behavioural and neuropharmacological analysis 351

Wilson, H., see Mathew, R.J. 298

Wilson, L., see Seidel, W.F., et al. 194

Woolverton, W.L., see Kamien, J.B. 368

Young, S.N., Smith, S., Pihl, R.O., Ervin, F.R.
Tryptophan depletion causes a rapid lowering of mood in normal males 173

Yuwiler, A., see Olds, M.E. 484

Zerbe, G., see Crowley, T.J., et al. 250